1. PRLog Home
  2. Business Index
  3. Pressroom Index
  4. Press Releases Home
  1. About
  2. Press Room
  3. Contact
Filter By Industry
Filter By Tag

Press Room

NAPSRx Press releases

1 - 10 of 265 Press Releases

Oct 20, 2014
There are many reasons why pharmaceutical sales positions are desired by many aspiring job seekers in the healthcare industry.

Oct 17, 2014
Roche revealed an impressive financial report for their third quarter with notable sales growth in the pharmaceuticals division.  Group sales were 11.78 billion Swiss francs ( $12.5 billion) up 5% compared to last year.

Oct 16, 2014
The U.S. Food and Drug Administration has approved two new therapies for the treatment of idiopathic pulmonary fibrosis (IPF) these are Roche’s Esbriet (pirfenidone) and Boehringer Ingelheim’s  OFEV™ (nintedanib*).

Oct 15, 2014
Astellas Pharma Inc and an investigator at Harvard Medical will collaborate on discovering the pathologic mechanism and identifying therapeutic treatments for retinitis pigmentosa.

Oct 14, 2014
Johnson & Johnson (NYSE: JNJ) has announced their third quarter earnings for 2014 with sales amounting to $18.5 billion, up 5.1% versus the third quarter of 2013.

Oct 13, 2014
The United States Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for Pfizer's palbociclib. The NDA submitted requests approval of palbociclib, in combination with letrozole.

Oct 10, 2014
According to the Decisions Resources Group, the chronic heart failure market will grow from approximately $2.9 billion in 2013 to $8.9 billion in 2023.

Oct 09, 2014
Benralizumab, AstraZeneca’s novel investigational monoclonal antibody to treat patients with severe, uncontrolled asthma and elevated levels of eosinophils (inflammatory white blood cell)  has produced optimistic safety and efficacy clinical data...

Oct 08, 2014
Chimerix, Inc. (Nasdaq:CMRX), is a biopharmaceutical company focused on developing and commercializing novel, oral antivirals in areas of high unmet medical need.

Oct 07, 2014
Actavis will acquire Durata’s novel antibiotic DALVANCE - the first and only IV antibiotic approved for the treatment of ABSSSI.

RSS Feed for NAPSRx Press Releases